TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Allyx Therapeutics Expands into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 After Acceptance of Investigational New Drug (IND) Application

Wednesday, March 06, 2024

Allyx Therapeutics, a biotechnology company in the clinical stages, has recently gained approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug Application (IND) for ALX-001. This milestone enables clinical trials in Parkinson’s disease, marking a significant advancement in their efforts to develop an oral therapy for neurodegenerative diseases.

CEO Stephen Bloch, M.D., stressed the urgency of exploring how ALX-001's unique mechanism, targeting synapses via mGluR5, could bring tangible benefits to individuals with Alzheimer’s and Parkinson’s. With substantial funding support, including over $20 million from esteemed organizations like the National Institutes of Health and The Michael J. Fox Foundation, Allyx is well-positioned to advance its research.

Tim Siegert, Ph.D., Allyx's COO, expressed appreciation for The Michael J. Fox Foundation's support, which accelerates their Parkinson’s research efforts. Their collaboration aims to swiftly translate scientific breakthroughs into clinical applications, offering hope for those affected by neurodegenerative conditions.

Brian Fiske, Ph.D., Chief Scientific Officer at The Michael J. Fox Foundation, expressed enthusiasm for assessing ALX-001's potential in Parkinson’s disease, building on its success in Alzheimer’s research.

ALX-001, a silent allosteric modulator of mGluR5, selectively blocks harmful receptor activation while preserving crucial glutamate signaling for cognition. This innovative approach targets synaptic dysfunction and loss associated with neurodegenerative diseases, offering a novel therapeutic avenue. Originating from Bristol Myers Squibb and Yale University, Allyx Therapeutics holds exclusive rights to ALX-001, driving its development towards transformative treatments.

Recent studies, including a Phase 1b multiple ascending dose study, have shown promising results, further validating ALX-001's potential. The upcoming presentation of these findings at the AD/PD™ 2024 Conference underscores the company's commitment to advancing scientific understanding and clinical progress in neurodegenerative research.

 

Source: globenewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit